Episode Details

Dr. Ali Tinazli: Quick Turn Diagnostics

Ep. 24

Orange County-based medical diagnostic company Fluxergy has taken the next step toward getting a high-speed test for COVID-19 available for use. Fluxergy submitted an emergency use authorization request to the U.S. Food and Drug Administration Center For Devices and Radiological Health, seeking an authorization that would permit medical professionals to begin using the company’s test system as a COVID-19 diagnostic at the point-of-care. Advanced rapid point-of-care tests for COVID-19 may have the potential to save significant time compared to standard lab tests that must be shipped to centralized laboratories for processing. Fluxergy’s on-site sample- to-answer test for COVID-19 requires a very small sample, typically a nasal swab, which is mixed with a reagent solution, loaded onto a card and inserted into the analyzer in a two-step procedure.

In this episode of DeviceAlliance’s Medtech Radio we with speak CCO of Fluxergy, Dr. Ali Tinazli. He also serves as Business Partner & Strategy Advisor
with Immunaccel, and is a Member of the Strategic Advisory Board of InnVentis Ltd. Join us as we discuss Fluxergy's goal to make laboratory testing accessible everywhere, the challenges facing current labs, and how our current environment is acting as a catalyst for the next generation of medical device innovation.

24

Follow the great work Dr. Ali and team are doing at Fluxergy.

Thanks for listening! Please share our podcast on LinkedIn, Twitter, and Facebook, and stay tuned for our next episode!

OTHER MEDTECH RADIO EPISODES

  • All
  • Entrepreneurship/Startups
  • Leadership Spotlight
  • Marketing & Product Development
  • Professional Development
  • Women in MedTech
  • Young Professionals

Live DA Event: Critical Thinking on Clinical Trial Success | Ep.43

You’ve got a great idea for a medical device!  Now what? Most errors in clinical trials are a result of poor planning. Fancy statistical methods cannot rescue design flaws. Thus careful planning with clear foresight is absolutely crucial for clinical trial success.   With the explosion of Medtech opportunities for startups, what are the current